- Home
- PRGS vs OCS Comparison
PRGS vs OCS Comparison
Compare PRGS & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRGS | OCS |
|---|---|---|
| Founded | 1981 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 1991 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRGS | OCS |
|---|---|---|
| Price | $41.32 | $28.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $66.33 | $39.57 |
| AVG Volume (30 Days) | ★ 822.0K | 242.6K |
| Earning Date | 01-20-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.79 | N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $977,831,000.00 | $991,999.00 |
| Revenue This Year | $3.49 | $14.53 |
| Revenue Next Year | $2.17 | $691.13 |
| P/E Ratio | $25.10 | ★ N/A |
| Revenue Growth | ★ 29.79 | N/A |
| 52 Week Low | $38.54 | $14.00 |
| 52 Week High | $65.50 | $28.01 |
Technical Indicators
Market Signals| Indicator | PRGS | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 46.24 | 84.37 |
| Support Level | $38.54 | $26.13 |
| Resistance Level | $47.25 | $27.43 |
| Average True Range (ATR) | 1.69 | 1.38 |
| MACD | 0.04 | 0.42 |
| Stochastic Oscillator | 31.80 | 88.85 |
Price Performance
Historical ComparisonAbout PRGS Progress Software Corporation (DE)
Progress Software Corporation provides software operate in one operating segment: software products for the development, deployment, and management of responsible, AI-powered applications and digital experiences. Following are products: Chef, Corticon, Data Direct, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, WhatsUp Gold. Geographical regions include United States, Canada, EMEA, Latin America, and Asia Pacific.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.